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Currently, there is great interest in identifying genetic variants that contribute to the risk of developing autism spectrum disor-
ders (ASDs), due in part to recent increases in the frequency of diagnosis of these disorders worldwide. While there is nearly 
universal agreement that ASDs are complex diseases, with multiple genetic and environmental contributing factors, there is 
less agreement concerning the relative importance of common vs rare genetic variants in ASD liability. Recent observations 
that rare mutations and copy number variants (CNVs) are frequently associated with ASDs, combined with reduced fecundity 
of individuals with these disorders, has led to the hypothesis that ASDs are caused primarily by de novo or rare genetic muta-
tions. Based on this model, large-scale whole-genome DNA sequencing has been proposed as the most appropriate method for 
discovering ASD liability genes. While this approach will undoubtedly identify many novel candidate genes and produce im-
portant new insights concerning the genetic causes of these disorders, a full accounting of the genetics of ASDs will be incom-
plete absent an understanding of the contributions of common regulatory variants, which are likely to influence ASD liability 
by modifying the effects of rare variants or, by assuming unfavorable combinations, directly produce these disorders. Because 
it is not yet possible to identify regulatory genetic variants by examination of DNA sequences alone, their identification will 
require experimentation. In this essay, I discuss these issues and describe the advantages of measurements of allelic expression 
imbalance (AEI) of mRNA expression for identifying cis-acting regulatory variants that contribute to ASDs.  
common-disease-common-variant model, common-disease-rare-variant model, copy number variant (CNV), allelic ex-
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ASDs comprise a group of complex disorders characterized 
by language impairments, social deficits and repetitive and 
stereotyped patterns of behaviors [1]. The three primary 
forms of ASD––autistic disorder, pervasive developmental 
disorder-not otherwise specified and Asperger’s syn-
drome––are usually diagnosed in early childhood and are 
widely considered to be caused by abnormalities in neuro-
development [2]. The prevalence of ASD among 8-year 
olds in the United States is estimated to be about 9 in 1000 
(0.9%), with an approximately 4-fold higher occurrence in 
males compared to females [3]. The prevalence of ASD in 
Asia and Europe is reported to be 0.6%–1% [3]. Twin and 
family studies have shown that ASD are strongly influenced 
by genetics, with an estimated heritability of 0.9 for autistic 
disorder [4]. An estimated 7%–10% of ASD cases are 
strongly associated with “syndromic” disorders caused by 
mutations in single genes (e.g., FMR1 in fragile X syn-
drome [5], MECP2 in Rett syndrome, and TSC1 and TSC2 
in tuberous sclerosis complex) or by deletions or duplica-
tions affecting multiple genes (e.g., deletion of 16p11.2 [6,7] 
or maternal duplication/triplication of 15q11-q13 [8,9]). The 
genetic basis of non-syndromic (i.e., “idiopathic”) ASD, 
however, is poorly understood [10].  
Two paradigms for the genetic “architecture” of ASD, 
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the common-variant and rare-variant models, respectively, 
have provided the basis for attempts to experimentally iden-
tify ASD liability genes [10]. Until recently, the com-
mon-variant model was widely assumed to apply to ASD 
and provided the rationale for many candidate gene and 
genome-wide association studies. The relatively small yield 
of novel ASD susceptibility genes identified in these studies, 
however, has recently stimulated interest in the rare-variant 
model. The idea that rare, highly penetrant genetic variants, 
rather than common variants of modest effect, are the pri-
mary of cause of many common disorders, including ASD 
and schizophrenia, has been forcibly argued in recent re-
views [11,12]. 
The goal of this essay is to briefly describe the strengths 
and weaknesses of these two models as they apply to ASD 
and to discuss the probable need to include common regu-
latory variants, i.e., genetic variants that influence mRNA or 
protein expression, rather than change the amino acid se-
quence of the encoded protein, in any accounting of the 
genetic basis of ASD and the methods by which these vari-
ants can be identified.  
1  The common-variant model for ASD 
The common-variant hypothesis [13] proposes that suscep-
tibility to common disorders depends upon combinations of 
genetic variants that occur frequently (population frequen-
cies1%), with some combinations increasing susceptibility 
and others possibly providing protection against disorders. 
Individually, disease susceptibility alleles are proposed to 
make only a modest contribution to disease and, therefore, 
not be subject to severe selection that would rapidly elimi-
nate them from the population. Mathematical modeling 
shows that in the absence of strong negative selection, many 
of the genetic variants that contributed to common disorders 
in our “out-of-Africa” ancestors would continue to persist in 
modern populations [14]. Thus, ancient genetic variants 
found in current human populations can be expected to con-
tribute to current common disorders. Examples of common, 
and possibly ancient, variants that influence the risk of 
complex diseases include the apolipoprotein E4 (APOE-4) 
allele in Alzheimer’s disease [15,16], the transmembrane 
conductance regulator-F508 deletion (CFTR-F508) allele 
in cystic fibrosis [17], and the complement factor H (CFH)-      
Y402H allele in age-related macular degeneration [18]. 
Because individuals with ASD have reduced reproduc-
tive fitness, it would seem that there should be severe selec-
tion against the genetic variants that cause this disorder. 
Other observations, however, suggest that ASD-related var-
iants may exist in the larger population under less stringent 
negative selection. For example, sub-clinical ASD-like traits 
can be detected in the relatives of “multiplex” families who 
have two-or-more children with ASD [19] and some au-
tism-associated genetic markers have been shown to corre-
late with social communication phenotypes in the general 
population [20]. From this perspective, clinically diagnosed 
ASD can be thought to occupy the extreme region of a 
spectrum of genetically influenced behaviors that extends 
over the entire population. Such a model argues in favor of 
contributions to ASD from multiple common genetic vari-
ants. Individuals in the clinical range of the spectrum, could 
simply be those who have inherited unfortunate combina-
tions of variants, which in isolation do not produce debili-
tating phenotypes.    
Common genetic variants linked to ASD susceptibility 
have, in fact, been identified in genome-wide association 
studies. Examples include a single nucleotide polymor-
phism (SNP) located between the cadherin genes CDH9 and 
CDH10 on chromosome 15p14.1 and a SNP near the sem-
aphorin 5A gene SEMA5A on chromosome 5p15 [2123]. 
The predicted effect sizes associated with these variants, 
however, are small and functional variants that change the 
properties of specific genes have not yet been identified. 
Stronger evidence for association with ASD has been ob-
tained in family-based linkage and association studies for a 
common variant (rs7794745) in the neurexin super-family 
gene CNTNAP2 [2426]. The majority of ASD candidate 
gene-based association studies, however, have produced 
inconsistent evidence for contributions of common variants 
[27]. In addition, a recent study has raised the possibility 
that many statistically significant associations between 
common variants and phenotypes may actually be “synthet-
ic” associations driven by rare causal variants [28]. The 
failure of association studies to clearly identify multiple 
genes that contribute to ASD has been interpreted by many 
investigators as evidence that common variants do not sig-
nificantly contribute to these disorders.  
2  The rare variant model for ASD 
The rare-variant model for common disorders proposes that 
disease susceptibility depends upon many individually rare 
(population frequencies < 1%), highly penetrant genetic 
variants [29–31]. Rare variants include point mutations, 
small and large deletions and duplications and chromosomal 
rearrangements that disrupt the structure or function of 
genes. Especially for disorders with reduced fertility, muta-
tions that cause the disorder are proposed to arise de novo in 
the gametes that produced the affected individual or to be 
propagated for only a few generations within families. Due 
to strong negative selection, such mutations would never 
become “common” variants in the population. 
One of the most exciting developments in research on the 
etiology of ASD has been the recent discovery that many 
cases of ASD are associated with rare deletions or duplica-
tions, termed copy number variants (CNVs), that directly or 
indirectly affect genes related neurodevelopment and/or 
synaptic functions [32–35]. Genes affected by CNVs linked 
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to ASD include NRXN1 [36], NLGN4X [37], APBA2 [38], 
SYNGAP1 [35], DLGAP2 [35], SHANK2 [35,39], and 
SHANK3 [34]. DNA sequencing has also identified rare 
missense and nonsense mutations in several of these genes 
in ASD patients [10].  
Although, evidence for the involvement of rare CNVs 
and other genetic variants in ASD is rapidly accumulating, 
association with ASD is often based simply on the presence 
of an excess number of these variants among cases com-
pared to controls, with some variants detected in cases only 
a few times [32–35]. The observation that many rare CNVs 
and point mutations associated with ASD are also found in 
individuals with mental retardation or schizophrenia [40] 
and, at lower frequencies, in control populations [32–35], 
suggests that individual variants must interact with other 
factors to produce specific pathological phenotypes. Alt-
hough combinations of rare variants could in principal cause 
ASD, it is statistically more likely that that individual rare 
variant interact with common variants to produce patholog-
ical or protective effects. The following sections discuss 
reasons why common regulatory genetic variants are likely 
to contribute to these disorders and methods by which these 
variants can be detected. 
3  The potential importance of regulatory genetic 
variants in ASD 
Genetic variation located outside of protein coding regions 
is common in the human genome and is thought to play a 
major role in producing phenotypic differences among indi-
viduals, including susceptibility to disease [41–46]. The 
majority of these variants are likely to be evolutionarily 
“neutral” and lack physiological effects. Many genetic var-
iants in non-coding DNA regions, however, have been 
shown to regulate gene expression by modulating mRNA 
transcription, splicing or stability [47]. Although most reg-
ulatory variants are located in close proximity to the genes 
they influence, this is not always the case. “Cis-acting” var-
iants that exert strong influences on mRNA expression (via 
mechanisms not involving diffusible factors), for example, 
have been detected at great distances (>10–1000 kb) from 
the start of transcription [48]. A well-documented example 
is a variant (13910×T) common in European populations 
located 13 kb upstream from the human lactase gene LCT 
that allows expression of lactase to persist in adults, thereby 
affording protection against adult-type hypolactasia [49].   
Compared to mutations that alter protein structure or 
gene copy number, regulatory variants can be expected to 
produce “milder” effects by changing levels of gene expres-
sion rather than completely knocking out gene function. In 
addition to directly contributing to disease susceptibility, 
common regulatory variants have been shown to modulate 
the effects of rare pathogenic variants [50,51].  
There are several reasons why regulatory variants are 
difficult to detect in genetic association studies. In candidate 
gene-based association studies, for example, cis-acting reg-
ulatory variants located at a great distance from the candi-
date gene may not be selected for study. Using mRNA ex-
pression as a phenotype, it is often possible to identify dis-
tant regulatory variants and employ these as markers for 
linking gene to phenotype [52].  
More generally, pathologic (or protective) effects of reg-
ulatory variants may be hard to detect because, individually, 
they make only small contributions to gene expression. In 
fact, recent studies have shown that mRNA expression for 
some genes is a “complex trait”, influenced by multiple 
regulatory elements [53–55]. Especially in the case of large 
genes, individual regulatory variants may reside within in-
dependent haplotype blocks. For these genes, studies look-
ing for statistical associations genetic marker-by-genetic 
marker may fail to detect contributions of individual vari-
ants. Using RNA expression as a phenotype allows the con-
tributions of multiple regulatory elements to be directly as-
sessed [53–55], thereby facilitating the selection of optimal 
sets of markers for genetic association studies. 
Similar arguments hold for regulatory variants that in-
fluence genes within the same biological pathway or system: 
the effects of variants within individual genes may be small, 
but variants in multiple genes may combine to produce 
large effects [56]. To deal with these complexities, there are 
clear advantages to independently identifying genetic vari-
ants that, singly or in combination, influence mRNA ex-
pression of key genes and using these (or surrogate “indica-
tor” SNPs) as markers in genetic association studies. Spe-
cifically, identifying high- and low-expression alleles for 
key genes may help to predict how combinations of these 
alleles influence disease susceptibility or protection. For 
example, a low-expression variant for mRNA encoding an 
enzyme that performs a rate-limiting step in the biosynthesis 
of a neurotransmitter might produce a significant phenotypic 
effect only in individuals who also harbor a high-expression 
variant for mRNA encoding an enzyme that degrades the 
neurotransmitter. It is possible that interactions among 
high-and low-expression alleles account for much of the 
“missing heritability” of complex diseases [57].  
4  Detecting regulatory variants 
The discovery of rare CNVs and point mutations that asso-
ciate with ASD has strengthened the argument that large-     
scale DNA sequencing will be an efficient method for dis-
covering additional genetic variants that contribute to these 
disorders. Although this strategy is compelling, and large-      
scale whole-genome or exome-centered sequencing is likely 
to produce a wealth of novel candidate genetic variants 
[58,59], it is not the appropriate method for discovering 
regulatory variants. Bioinformatic tools designed to identify 
variants that influence RNA transcription, splicing, and sta-
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bility are currently far from exact, making it unlikely that 
most variants that affect RNA expression can be predicted 
from genomic DNA sequences alone. Instead, experiments 
will be required to identify regulatory variants, for example, 
by quantifying mRNA expression in the physiologically 
relevant tissue and identifying genetic variants that correlate 
with high- or low-levels of expression.  
Methods used to quantify mRNA expression include 
Northern blotting, polymerase chain reaction (PCR), and 
microarrays. Using these techniques to analyze regulatory 
variants that contribute to ASD, however, is complicated by 
the need to measure mRNA expression in human brain tis-
sue. Brain samples are usually obtained at autopsy from 
“normal” individuals, and there is little that the investigator 
can do to control for variables that may influence mRNA 
expression and quality, such as postmortem interval, tissue 
pH, cause of death, medical and drug histories [60]. These 
“external” factors introduce considerable variability into 
measurements of mRNA expression and make it difficult to 
make meaningful comparisons among samples. Studying 
mRNA expression in brain tissue using “high-throughput” 
methods such as microarrays is also complicated by the 
heterogeneity of cell types, the 10-to-20-fold excess of glial 
cells over neurons, and the restriction of expression of many 
mRNAs to highly localized nuclei, such as serotonin-related 
mRNAs in neurons in raphe nuclei of the brain stem.   
As an alternative to the above methods, we [61,62] and 
others [63,64], have used PCR-based, allele-specific meth-
ods for quantifying mRNA expression in individual samples 
of human brain. In these methods, a SNP in the mature 
mRNA serves as a molecular marker to distinguish mRNAs 
derived from each of the two alleles present in individuals 
who are heterozygous for the SNP. After isolation of total 
RNA from frozen, non-fixed sections of human brain, 
cDNA is prepared by reverse-transcription using oligo-dT 
or gene-specific primers. Segments of the resulting cDNA 
containing the marker SNP are then PCR-amplified using 
synthetic oligonucleotide primers that flank the marker 
SNP. Finally, the relative amounts of PCR products de-
rived from each allele are quantified using a primer-exten-      
sion assay [61–64] or by DNA sequencing [65]. “Allelic 
expression imbalance” (AEI) ratios obtained from these 
measurements are subsequently adjusted to account for ex-
perimental bias using a correction factor determined by 
carrying out the assays using genomic DNA as the initial 
template [61].  
These assays are highly reproducible and allow allelic 
expression ratios to be determined with an error of 20%, or 
less. The accuracy and reproducibility of these measure-
ments come from that fact that AEI ratios are determined 
for individual brain samples, where each allele has been 
exposed to the same “external” factors. Any difference in 
mRNA expression between alleles is presumed to reflect the 
influence of cis-acting genetic variants that differentially 
regulate each allele.  
Once AEI has been detected, the regulatory variants re-
sponsible for the differential mRNA expression or alterna-
tively an “indicator” SNPs (iSNPs) that are tightly linked to 
the regulatory variant can often be identified through an 
association analysis with genotyped SNPs in the neighbor-
hood of the gene. An efficient method for identifying indi-
cator SNPs for many genes has been evaluate to SNPs in the 
region of the gene for correlations between SNP heterozy-
gosity and AEI and lack of correlation between SNP ho-
mozygosity and AEI [62]. For SNPs that satisfy these crite-
ria, “high”- and “low”-expression alleles are identified by 
plotting absolute mRNA expression levels (quantified by 
real-time PCR) versus the SNP genotypes (AA, Aa, aa) [62]. 
Indicator SNPs identified by these assays can be used as 
genetic markers in case-control association studies. Identi-
fication of the actual regulatory variant (presumably tightly 
linked to the iSNP) often requires additional experiments, 
including resequencing of chromosomal segments in link-
age disequilibrium with the iSNP and/or testing the effects 
of putative regulatory variants on gene expression, RNA 
transcript splicing or mRNA stability in vitro [64,66,67].   
5  How to proceed  
Genetic markers obtained by the above procedures are ideal 
for testing the hypothesis that common regulatory variants 
contribute to ASD. Because identifying regulatory variants 
is labor-intensive, it is most suitable for use in candidate 
gene-based studies. Candidate genes may be selected based 
on biological theories concerning the etiology of the disor-
der (in the case of ASD, for example, selecting genes relat-
ed to neurodevelopment or synaptic function) or based on 
information about specific genes or biological pathways 
previously identified in genetic association or linkage stud-
ies. In addition, genes that are influenced by recurrent or 
rare CNVs linked to ASD are an obvious choice.  
Because deletion or duplication of a gene in a CNV only 
affects one of a pair of autosomal genes, a “normal” copy of 
the gene is usually present on the other chromosome. For 
this reason, CNVs are most likely to produce pathological 
effects when they affect “dose-sensitive” genes, for which 
deletions result in “haploinsufficiency” and duplications 
result in inappropriate over-expression. In either case, the 
expected change in gene expression is only 50%, down or 
up. Surveys of mRNA expression human tissues, including 
brain, show that allele-specific differences in mRNA ex-
pression of 1.5–2-fold are common [68,69]. Regulatory 
variants can therefore be expected to mimic the effects of 
single-gene deletions and duplications. For example, indi-
viduals harboring two “low-expression” alleles of a dose-      
sensitive autosomal gene, each expressing 50% less than 
average, might experience the same risk for disease as indi-
viduals who harbor a rare CNV that of deletes one copy for 
the gene. 
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Relatively modest changes in gene expression such as 
those described above have, in fact, been shown to have 
dramatic effects when they occur in dose-sensitive genes. 
Good examples are rare CNVs that result in duplication of 
the amyloid precursor protein gene APP. Individuals who 
harbor duplications, and therefore carry three copies of the 
APP gene, develop Alzheimer’s disease (AD) in their early 
fifties, about 30 years earlier than the typical age-of-onset of 
sporadic AD [70]. Promoter mutations that cause modest 
increases in APP expression have also been shown to result 
in early onset AD and to occur at a higher frequency than 
APP coding region variants in at least one AD population 
[71]. Similarly, individuals with triplication of the alpha-      
synuclein gene SNCA develop early-onset Parkinson’s dis-
ease [72,73]. Together, these examples show that even 
modest changes in expression of dose-sensitive genes can 
have a major influence on disease susceptibility and onset. 
As mentioned above, in addition to producing pathologi-
cal effects, regulatory variants are also likely to play im-
portant roles in modulating the effects of gene duplication 
and deletions produced by CNVs. For example, the pres-
ence of a “low-expression” allele of an autosomal gene 
might ameliorate the effects of duplication of the gene on its 
paired chromosome, while a high-expression allele might 
have the opposite effect. The same possibility holds for 
“high-expression” and “low-expression” alleles paired with 
pathogenic deletion CNVs. The identification of genetic 
markers that predict high- and low-mRNA expression for 
genes located within ASD-associated CNVs will be useful 
for exploring these possibilities.  
6  Summary 
The momentum is currently swinging towards the rare-  
variant model for ASD, a movement driven both by the 
failure of genome-wide association studies to identify 
common causal genetic variants and the discovery of rare 
pathogenic CNVs. Although intensive DNA sequencing is 
likely to identify many novel mutations and CNVs that con-
tribute to ASD, the inability to identify regulatory variants 
is likely to leave much of the genetic etiology of these dis-
orders unexplained.   
We hypothesize that a complete description of the genet-
ics of ASD is likely to require an accounting of the influ-
ences of common regulatory variants. We propose that ex-
amining allele-specific differences in mRNA expression for 
genes located within ASD-associated CNVs will prove to be 
an effective method for discovering these variants.   
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